DiaMedica Therapeutics Ownership
| DMAC Stock | USD 4.70 0.52 12.44% |
Shares in Circulation | First Issued 2005-03-31 | Previous Quarter 38.1 M | Current Value 42.8 M | Avarage Shares Outstanding 8.8 M | Quarterly Volatility 11 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
DiaMedica |
DiaMedica Stock Ownership Analysis
About 26.0% of the company shares are held by company insiders. The book value of DiaMedica Therapeutics was currently reported as 1.35. The company recorded a loss per share of 0.56. DiaMedica Therapeutics last dividend was issued on the 15th of November 2018. The entity had 1:20 split on the 15th of November 2018. DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota. Diamedica Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 14 people. To learn more about DiaMedica Therapeutics call Dietrich MBA at (763) 496-5454 or check out https://www.diamedica.com.Besides selling stocks to institutional investors, DiaMedica Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different DiaMedica Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align DiaMedica Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
DiaMedica Therapeutics Quarterly Liabilities And Stockholders Equity |
|
DiaMedica Therapeutics Insider Trades History
About 26.0% of DiaMedica Therapeutics are currently held by insiders. Unlike DiaMedica Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against DiaMedica Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of DiaMedica Therapeutics' insider trades
DiaMedica Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as DiaMedica Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading DiaMedica Therapeutics backward and forwards among themselves. DiaMedica Therapeutics' institutional investor refers to the entity that pools money to purchase DiaMedica Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Ronald Blue Trust, Inc. | 2024-09-30 | 44.2 K | Susquehanna International Group, Llp | 2024-06-30 | 43.4 K | Catalyst Financial Partners Llc | 2024-09-30 | 38.5 K | Jefferies Financial Group Inc | 2024-09-30 | 26 K | Citigroup Inc | 2024-09-30 | 22.1 K | Stonebridge Capital Advisors Llc | 2024-09-30 | 17.5 K | Dimensional Fund Advisors, Inc. | 2024-09-30 | 17 K | Bnp Paribas Arbitrage, Sa | 2024-06-30 | 15.2 K | Jane Street Group Llc | 2024-06-30 | 15.1 K | Cooperman Leon G | 2024-09-30 | 1.5 M | Vanguard Group Inc | 2024-09-30 | 1 M |
DiaMedica Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific DiaMedica Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on DiaMedica Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases DiaMedica Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
DiaMedica Therapeutics Outstanding Bonds
DiaMedica Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. DiaMedica Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most DiaMedica bonds can be classified according to their maturity, which is the date when DiaMedica Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View |
DiaMedica Therapeutics Corporate Filings
8K | 13th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10Q | 7th of August 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
| 18th of July 2024 Other Reports | ViewVerify | |
| 10th of July 2024 Other Reports | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether DiaMedica Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of DiaMedica Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Diamedica Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Diamedica Therapeutics Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DiaMedica Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade DiaMedica Stock refer to our How to Trade DiaMedica Stock guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DiaMedica Therapeutics. If investors know DiaMedica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DiaMedica Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.56) | Return On Assets (0.24) | Return On Equity (0.35) |
The market value of DiaMedica Therapeutics is measured differently than its book value, which is the value of DiaMedica that is recorded on the company's balance sheet. Investors also form their own opinion of DiaMedica Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is DiaMedica Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DiaMedica Therapeutics' market value can be influenced by many factors that don't directly affect DiaMedica Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DiaMedica Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if DiaMedica Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DiaMedica Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.